Abbott Laboratories (NYSE:ABT) EVP Mary Moreland Sells 613 Shares

Abbott Laboratories (NYSE:ABT) EVP Mary Moreland sold 613 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the sale, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $113.55 on Wednesday. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23. The company’s fifty day simple moving average is $116.90 and its 200-day simple moving average is $125.00. The firm has a market cap of $197.31 billion, a PE ratio of 30.52, a P/E/G ratio of 1.82 and a beta of 0.74. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ABT shares. Leerink Partners dropped their price target on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research note on Friday, January 30th. Argus reduced their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Sanford C. Bernstein lowered their price target on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Evercore decreased their target price on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Finally, Oppenheimer dropped their target price on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $137.05.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: FDA approval of the redesigned CardioMEMS Hero remote heart‑failure monitor — a smaller, lighter reader aimed at improving patient convenience and clinician workflows — strengthens Abbott’s position in heart‑failure management and could increase adoption and revenue over time. How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story
• Neutral Sentiment: Multiple insider sales disclosed (several senior/executive officers sold small blocks of shares on Mar. 2). The transactions were modest relative to their remaining holdings, suggesting routine portfolio management rather than a clear signal of company deterioration. John A. Jr. Mccoy Insider Sale
• Negative Sentiment: Near-term earnings pressure: Q4 EPS met estimates but revenue came in below consensus ($11.46B vs. ~$11.80B), which, together with recent softer quarterly trends, has left analysts cautious and weighed on the stock. Abbott (ABT) Stock Sinks As Market Gains: Here’s Why
• Negative Sentiment: Shares have underperformed the market over the past six months amid disappointing near‑term results and investor skepticism, which increases sensitivity to any incremental downside news. 2 Reasons to Like ABT and 1 to Stay Skeptical

Hedge Funds Weigh In On Abbott Laboratories

A number of institutional investors have recently modified their holdings of the business. Charles Schwab Trust Co boosted its stake in shares of Abbott Laboratories by 109.8% in the 3rd quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock valued at $3,939,000 after purchasing an additional 15,394 shares during the last quarter. Asset Management One Co. Ltd. lifted its holdings in Abbott Laboratories by 2.4% in the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock valued at $115,032,000 after buying an additional 19,966 shares during the period. Nordea Investment Management AB grew its holdings in Abbott Laboratories by 6.1% during the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock worth $43,785,000 after acquiring an additional 18,974 shares during the period. AE Wealth Management LLC boosted its position in shares of Abbott Laboratories by 20.8% during the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock valued at $8,774,000 after purchasing an additional 11,264 shares in the last quarter. Finally, Mawer Investment Management Ltd. lifted its stake in Abbott Laboratories by 5.9% in the third quarter. Mawer Investment Management Ltd. now owns 1,255,780 shares of the healthcare product maker’s stock valued at $168,199,000 after buying an additional 70,122 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.